Efficacy of Comprehensive Therapy, Including Pharmacotherapy and Dietary/Lifestyle Guidance, on Renoprotection in Patients with Chronic Kidney Disease

Efficacy of Comprehensive Therapy, Including Pharmacotherapy and Dietary/Lifestyle Guidance, on Renoprotection in Patients with Chronic Kidney Disease - Efficacy of Comprehensive Therapy in Patients with Chronic Kidney Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058718

Enrollment

500

Registered

2025-08-10

Start date

2025-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with CKD at our institution, as well as those who were diagnosed at a previous institution and subsequently referred to us.

Exclusion criteria

Exclusion criteria: 1, Individuals judged by the principal investigator to be unsuitable for the study. 2. Individuals who decline to participate in this study.

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be the rate of decline in renal function (annual change in eGFR), and we will evaluate the change in the eGFR slope before and after the initiation of the intervention.	—

Secondary

Measure	Time frame
To assess for cardiovascular (CVD) events during the follow-up period, as well as changes in albuminuria and/or proteinuria. Additional assessments include body weight and laboratory tests, such as a complete blood count (CBC) with differential, electrolytes (Na, K, Cl), minerals (P, Ca), total protein (TP), albumin (Alb), and C-reactive protein (CRP). We will also evaluate changes in exercise and dietary habits resulting from lifestyle guidance, and assess for frailty. Furthermore, we will investigate whether the primary cause of the chronic kidney disease is associated with any of these outcomes.	—

Measure

Time frame

To assess for cardiovascular (CVD) events during the follow-up period, as well as changes in albuminuria and/or proteinuria. Additional assessments include body weight and laboratory tests, such as a complete blood count (CBC) with differential, electrolytes (Na, K, Cl), minerals (P, Ca), total protein (TP), albumin (Alb), and C-reactive protein (CRP). We will also evaluate changes in exercise and dietary habits resulting from lifestyle guidance, and assess for frailty. Furthermore, we will investigate whether the primary cause of the chronic kidney disease is associated with any of these outcomes.

—

Countries

Japan

Contacts

Public ContactTakashi Maruyama

Nihon University School of Medicine Division of Nephrology, Hypertension and Endocrinology, Department of Medicine

maruyama.takashi@nihon-u.ac.jp0339728111

Outcome results